A PYMNTS Company

US: Abbott agrees to buy St. Jude Medical for $25 billion Giant health merger

By  |  May 1, 2016

Abbott announced that it will acquire St. Jude Medical in an effort to enhance its global scale and diversify its portfolio.

With the acquisition, Abbott will become a “premier medical device leader with top positioning in high-growth [CV] markets, including AF, structural heart and HF as well as a leading position in the high-growth neuromodulation market,” the company stated in a press release.

According to the release, St. Jude Medical’s strength in devices for cardiac rhythm management and treatment of HF and atrial fibrillation complements Abbott’s strength in devices for coronary intervention and transcatheter mitral valve repair, and will enable the combined company to compete in almost every facet of the CV market.

“The combined business will have a powerful pipeline ready to deliver next-generation medical technologies and offer improved efficiencies for health care systems around the world,” Miles D. White, chairman and CEO of Abbott, said in the release. The pipeline also includes products for diabetes, vision and neuromodulation, the company stated.

Full Content: The Wall Street Journal

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.